What analysts say
- Buy, sell, or hold?: Analysts strongly back Abaxis, with five of nine rating it a buy and the remainder rating it a hold. Analysts like Abaxis better than competitor IDEXX Laboratories overall. While analysts still rate the stock a moderate buy, they are a little more optimistic about it compared to three months ago.
- Revenue forecasts: On average, analysts predict $38.5 million in revenue this quarter. That would represent a rise of 10.2% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.16 per share. Estimates range from $0.13 to $0.20.
What our community says
CAPS All-Stars are solidly behind the stock with 95.7% assigning it an "outperform" rating. The community at large agrees with the All-Stars, with 90.5% awarding it a rating of "outperform." Fools are gung-ho about Abaxis, though the message boards have been quiet lately with only 62 posts in the past 30 days. Even with a robust four out of five stars, Abaxis' CAPS rating falls a little short of the community's upbeat outlook.
Abaxis' profit has risen year over year by an average of 13%.
For all our Abaxis-specific analysis, including earnings and beyond, add Abaxis to My Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.